Taste Of Capital
  • Politics
  • Investing
  • Business
  • Stock
Home Business UnitedHealth says it is facing DOJ investigation over Medicare billing practices
Business

UnitedHealth says it is facing DOJ investigation over Medicare billing practices

by admin July 25, 2025
July 25, 2025

UnitedHealth Group revealed Thursday it is facing a Justice Department investigation over its Medicare billing practices.

It comes after the Wall Street Journal reported in May that the Department of Justice is conducting a criminal investigation into the health-care giant over possible Medicare fraud. In response at the time, the company said it stands “by the integrity of our Medicare Advantage program.”

In July, the Journal also reported that the DOJ interviewed several doctors about UnitedHealth’s practices and whether they felt pressured to submit claims for certain conditions that bolstered payments from the Medicare Advantage program to the company.

That marked the second time this year that the insurer’s Medicare Advantage business has come under federal scrutiny. The Journal also reported in February that the DOJ is conducting a civil investigation into whether the company inflated diagnoses to trigger extra payments to its Medicare Advantage plans.

But in March, UnitedHealth moved a step closer to ending a yearslong legal battle with the DOJ that began with a whistleblower who alleged the company illegally withheld at least $2 billion through the Medicare Advantage program. A special master assigned to the case by the judge issued a recommendation in favor of UnitedHealth, saying the DOJ lacked evidence.

UnitedHealthcare’s Medicare and retirement segment, which includes the Medicare Advantage business, is UnitedHealth Group’s largest revenue driver, raking in $139 billion in sales last year.

The update in the probe comes after a tumultuous last year for UnitedHealthcare, the nation’s largest and most powerful private health insurer. Shares of UnitedHealthcare’s parent company, UnitedHealth Group, are down more than 42% for the year after it suspended its 2025 forecast amid skyrocketing medical costs, announced the surprise exit of former CEO Andrew Witty and grappled with the reported probe into its Medicare Advantage business.

The company’s 2024 wasn’t any easier, marked by a historic cyberattack and the torrent of public blowback after the murder of UnitedHealthcare’s CEO Brian Thompson.

This post appeared first on NBC NEWS

previous post
NatWest share price forecast before earnings: buy or sell?
next post
Centene stock plunges after surprise loss and soaring medical costs

Related Posts

FCC greenlights Paramount’s $8 billion merger with entertainment group Skydance

July 26, 2025

Microsoft’s Satya Nadella says job cuts have been ‘weighing heavily’...

July 26, 2025

UnitedHealth says it faces DOJ investigation over Medicare billing practices

July 25, 2025

Uber will let women drivers and riders request to avoid...

July 25, 2025

Alphabet beats earnings expectations, raises spending forecast

July 25, 2025

Businesses are cautiously spending on corporate travel as trade uncertainty...

July 24, 2025

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Stock News

    • GO Residential REIT drops on debut after oversubscribed $410M IPO

      July 26, 2025
    • Here’s why the Coursera stock price has surged and its next target

      July 26, 2025
    • Meta to halt political ads in EU from October 2025 amid legal uncertainty

      July 26, 2025
    • What is Lip-Bu Tan doing for Intel stock that’s different from Pat Gelsinger?

      July 26, 2025
    • LIDR stock skyrockets 150% after Nvidia deal, but analysts are still cautious: here’s why

      July 26, 2025
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: TasteOfCapital.com, its managers, its employees, and assigns (collectively "The Company") do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.
    Copyright © 2025 TasteOfCapital.com All Rights Reserved.

    Taste Of Capital
    • Politics
    • Investing
    • Business
    • Stock